/PDSB
PDSB Stock - PDS Biotechnology Corporation
Healthcare|BiotechnologyNASDAQ
$0.89+1.57%
+$0.01 (+1.57%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.19
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1023.5%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PDSB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.88 – $0.90
TARGET (TP)$10.00
STOP LOSS$0.82
RISK/REWARD1:130.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.10
52W High$2.20
52W Low$0.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-59,791 | $-57,326 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-36,321,195 | $-43,045,000 | $-41,672,421 | $-21,439,311 | $-14,902,386 |
| Net Income | $-37,610,384 | $-42,942,000 | $-40,854,855 | $-16,918,477 | $-14,847,380 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.03 | $-1.39 | $-1.43 | $-0.66 | $-0.89 |
Company Overview
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 1023.5% Upside
Now
$10
Low
$10
Average
$10
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 1st 2022 | B. Riley Securities | Initiation | Buy | $10 |
Earnings History & Surprises
PDSBBeat Rate
61%
Last 18 quarters
Avg Surprise
+3.7%
EPS vs Estimate
Beats / Misses
11/4
3 met exactly
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q1 24
+12.8%
$-0.34vs$-0.39
Q2 24
+18.9%
$-0.30vs$-0.37
Q3 24
+25.8%
$-0.23vs$-0.31
Q4 24
0.0%
$-0.29vs$-0.29
Q1 25
+27.6%
$-0.21vs$-0.29
Q2 25
+16.0%
$-0.21vs$-0.25
Q3 25
+12.5%
$-0.21vs$-0.24
Q4 25
+9.5%
$-0.19vs$-0.21
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.24 | $-0.21 | +12.5% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.25 | $-0.21 | +16.0% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.29 | $-0.21 | +27.6% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.29 | $-0.29 | 0.0% | = MET |
Q3 2024 | Aug 13, 2024 | $-0.31 | $-0.23 | +25.8% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.37 | $-0.30 | +18.9% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-0.39 | $-0.34 | +12.8% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.42 | $-0.35 | +16.7% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.37 | $-0.37 | 0.0% | = MET |
Q2 2023 | May 15, 2023 | $-0.31 | $-0.32 | -3.2% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $-0.30 | $-0.67 | -123.3% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.26 | $-0.26 | 0.0% | = MET |
Q3 2022 | Aug 8, 2022 | $-0.30 | $-0.20 | +33.3% | ✓ BEAT |
Q2 2022 | May 11, 2022 | — | $-0.32 | — | — |
Q1 2022 | Mar 31, 2022 | $-0.24 | $-0.23 | +4.2% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.21 | $-0.22 | -4.8% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.20 | $-0.14 | +30.0% | ✓ BEAT |
Latest News
PDS Biotechnology shares are trading higher after the company announced a new composition of matter patent for PDS0101 in Japan.
📈 PositiveBenzinga•Dec 9, 2025, 04:59 PM
PDS Biotech Secures New Japan Patent Granting Broad Protection For PDS0101, Extending Global IP Coverage Into The 2040s
📈 PositiveBenzinga•Dec 9, 2025, 01:08 PM
PDS Biotechnology shares are trading higher after the company announced the FDA accepted its request for a Type C Meeting.
📈 PositiveBenzinga•Dec 2, 2025, 01:46 PM
PDS Biotech Schedules Type C Meeting With FDA To discuss Proposed Accelerated Approval Pathway For PDS0101
📈 PositiveBenzinga•Dec 2, 2025, 01:35 PM
B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $3
➖ NeutralBenzinga•Nov 25, 2025, 06:14 PM•Also:
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Raises Price Target to $15
📈 PositiveBenzinga•Nov 13, 2025, 06:22 PM
PDS Biotechnology Q3 EPS $(0.19) Beats $(0.22) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 12:31 PM
PDS Biotechnology Announces $5.3M Registered Direct Offering Of 5.8M Shares With Warrants At A Combined Price Of $0.91
📉 NegativeBenzinga•Nov 11, 2025, 08:35 PM•Also:
PDS Biotechnology shares are trading higher after the company highlighted immune biomarkers and anti-tumor activity for its PDS0101 and PDS01ADC programs at the SITC 2025 conference.
📈 PositiveBenzinga•Nov 10, 2025, 05:45 PM
PDS Biotechnology Highlights Immune Biomarkers And Anti-Tumor Activity Of PDS0101 And PDS01ADC At SITC 2025
📈 PositiveBenzinga•Nov 10, 2025, 01:55 PM
PDS Biotechnology Presents Clinical, Translational Data On Investigational Hpv16-Targeted Immunotherapy Pds0101 And Its Novel, Investigational Immunocytokine Pds01ADC
➖ NeutralBenzinga•Nov 10, 2025, 01:34 PM
PDS Biotechnology Announces National Cancer Institute To Present New Clinical Data To Highlight Details From Investigational Immunotherapy Platforms
📈 PositiveBenzinga•Oct 30, 2025, 12:18 PM
PDS Biotech Requests Meeting With FDA To Explore Expedited Approval Pathway For PDS0101 In HPV16-Positive Head And Neck Cancer
📈 PositiveBenzinga•Oct 29, 2025, 12:38 PM
PDS Biotech Reports 29.5-Month Median Overall Survival In Phase 2 Trial For Advanced Head And Neck Cancer; Says Encouraging Efficacy Signal Observed In Difficult To Treat Category Of Advanced Head And Neck Cancer Patients
📈 PositiveBenzinga•Sep 18, 2025, 12:47 PM
PDS Biotechnology Corp Files For Mixed Shelf Of Up To $200M
➖ NeutralBenzinga•Aug 29, 2025, 08:13 PM
PDS Biotechnology shares are trading higher after the company announced final topline survival data from its VERSATILE-002 Phase 2 clinical trial.
📈 PositiveBenzinga•Aug 25, 2025, 05:00 PM
PDS Biotechnology Reports Median Overall Survival Of 39.3 Months In HPV16-Positive Head And Neck Cancer Patients
📈 PositiveBenzinga•Aug 25, 2025, 12:34 PM
Frequently Asked Questions about PDSB
What is PDSB's current stock price?
PDS Biotechnology Corporation (PDSB) is currently trading at $0.89 per share. The stock has moved +1.57% today.
What is the analyst price target for PDSB?
The average analyst price target for PDSB is $10.00, based on 1 analyst.
What sector is PDS Biotechnology Corporation in?
PDS Biotechnology Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PDSB's market cap?
PDS Biotechnology Corporation has a market capitalization of $0.04 billion, making it a small-cap company.
Does PDSB pay dividends?
No, PDS Biotechnology Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
LVTX
LAVA Therapeutics N.V.
$1.74
Mkt Cap: $0.0B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to PDSB for comparison